Business
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
DENVER, May 15, 2025--TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"Expands commercial footprint, and invests further in new applications for TriNav already in use","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"Company to Host Conference Call and Webcast today at 8:00am ET","length":62,"tagName":"p","attribs":{}},{"type":"text","content":"DENVER, May 15, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended March 31, 2025, and provides an operational update and revised financial guidance.","length":436,"tagName":"p"},{"type":"text","content":""Our strong first quarter performance reflects the growing impact of our PEDD platform across a variety of solid tumor indications," said Mary Szela, President and CEO of TriSalus. "With the decision to partner Nelitolimod development following completion of the Phase 1 trials, and the expansion of our TriNav portfolio for a wide range of new applications, we are better positioned than ever to execute our long-term strategy.","length":443,"tagName":"p"},{"type":"text","content":""Following our recent private placement, we have made the strategic decision to further invest in our sales force expansion and clinical registries in new applications of our technology. We believe this growth-oriented strategy balances financial discipline with bold investments designed to drive long-term value creation. Accordingly, we’ve updated our 2025 guidance to reflect these strategic priorities. We are confirming our guidance of at least 50% revenue growth; however, due to increased investment, we no longer expect to be adjusted EBITDA-positive or cash flow-positive in 2025."","length":601,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Highlights","length":2...